fda glp-1 compounding warning october 2025 September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns – Partnership for Safe Medicines Out of Shortage, Into Controversy:

It does not provide nutrition plans, exercise programming, behavioral coaching, community support, or the holistic approach that research shows produces the best long-term weight management outcomes

Common gastrointestinal effects reported with GLP-1 therapy include: Nausea (commonly reported, especially during dose escalation) Constipation or diarrhoea Abdominal discomfort or bloating Reduced appetite and early satiety Regarding bowel movement colour specifically, changes in stool colour are not listed as adverse effects in UK SmPCs for GLP-1 receptor agonists

Sources Barakat GM et al

In a joint letter to the New England Journal of Medicine , the agencies stated that they had not yet reached a final conclusion regarding a possible causative relationship

Available from: 14

(accessed June 2022) 19Bain S